{
  "success": true,
  "sourceFile": "C:\\Users\\panik\\Documents\\GitHub\\Protcol2USDMv3\\input\\trial\\NCT03434379_IMPOWER150\\NCT03434379_IMPOWER150_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39
  ],
  "modelUsed": "gemini-3-flash-preview",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Intent-to-Treat Population",
        "text": "The ITT population is defined as all randomized patients, whether or not the patient has received the assigned study treatment.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "ITT",
        "populationDescription": "The ITT population is defined as all randomized patients, whether or not the patient has received the assigned study treatment.",
        "criteria": "All randomized patients"
      },
      {
        "id": "pop_2",
        "name": "Pharmacokinetic-Evaluable Population",
        "text": "The pharmacokinetic (PK)-evaluable population is defined as all patients who received any dose of study treatment and who have at least one post-baseline PK sample available.",
        "populationType": "PK/PD",
        "instanceType": "AnalysisPopulation",
        "label": "PK-Evaluable",
        "populationDescription": "The pharmacokinetic (PK)-evaluable population is defined as all patients who received any dose of study treatment and who have at least one post-baseline PK sample available.",
        "criteria": "Received any dose of study treatment AND has >=1 post-baseline PK sample"
      },
      {
        "id": "pop_3",
        "name": "PRO-Evaluable Population",
        "text": "The patient-reported outcome (PRO)-evaluable population will include all randomized patients who have a baseline and at least 1 post-baseline assessment.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "PRO-Evaluable",
        "populationDescription": "The patient-reported outcome (PRO)-evaluable population will include all randomized patients who have a baseline and at least 1 post-baseline assessment.",
        "criteria": "Randomized AND has baseline assessment AND has >=1 post-baseline assessment"
      },
      {
        "id": "pop_4",
        "name": "Safety Population",
        "text": "The safety population consists of all randomized patients who received at least one full or partial dose of any study treatment, with patients grouped according to the actual treatment received.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "SAF",
        "populationDescription": "The safety population consists of all randomized patients who received at least one full or partial dose of any study treatment, with patients grouped according to the actual treatment received.",
        "criteria": "Randomized AND received >=1 full or partial dose of study treatment"
      },
      {
        "id": "pop_5",
        "name": "Anti-Drug-Antibody-Evaluable Population",
        "text": "The anti-drug-antibody (ADA)-evaluable population is defined as all patients who received any dose of atezolizumab and who have at least one post-baseline ADA assessment.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "ADA-Evaluable",
        "populationDescription": "The anti-drug-antibody (ADA)-evaluable population is defined as all patients who received any dose of atezolizumab and who have at least one post-baseline ADA assessment.",
        "criteria": "Received any dose of atezolizumab AND has >=1 post-baseline ADA assessment"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Age",
        "code": "AGE",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Age",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Age at baseline"
      },
      {
        "id": "char_2",
        "name": "Sex",
        "code": "SEX",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Sex",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Gender of the participant"
      },
      {
        "id": "char_3",
        "name": "Race/Ethnicity",
        "code": "RACE/ETHNICITY",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Race/Ethnicity",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Race or ethnic background"
      },
      {
        "id": "char_4",
        "name": "Etiology",
        "code": "ETIOLOGY",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Etiology",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Baseline disease etiology"
      },
      {
        "id": "char_5",
        "name": "Disease Stage",
        "code": "DISEASE_STAGE",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Disease Stage",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Baseline disease stage"
      },
      {
        "id": "char_6",
        "name": "Child-Pugh Classification",
        "code": "CHILD-PUGH_CLASSIFIC",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Child-Pugh Classification",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Liver function classification"
      },
      {
        "id": "char_7",
        "name": "Baseline AFP",
        "code": "BASELINE_AFP",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Baseline AFP",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Alpha-fetoprotein level (<400 vs. >=400 ng/mL)"
      },
      {
        "id": "char_8",
        "name": "ECOG Performance Status",
        "code": "ECOG_PERFORMANCE_STA",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "ECOG Performance Status",
        "dataType": "Categorical",
        "instanceType": "Characteristic",
        "description": "Eastern Cooperative Oncology Group Performance Status (0 vs. 1)"
      }
    ],
    "summary": {
      "populationCount": 5,
      "characteristicCount": 8
    }
  }
}